Abstract
Study objectives: The potential sedative effect of dronabinol and the high expression of cannabinoid receptors on the hypoglossal motor nuclei makes this agent a good candidate for obstructive sleep apnea (OSA) pharmacotherapy, to be tested with atomoxetine, a noradrenergic reuptake inhibitor that reduced OSA severity in combination with oxybutynin. Here we tested the effect of atomoxetine 80 mg plus dronabinol (Ato-Dro) at two different doses (5 and 10 mg) vs. baseline and atomoxetine alone in a two-center, open-label, dose-escalating trial. The primary outcome was the effect of Ato-Dro vs. baseline on OSA severity (apnea-hypopnea index, AHI4). Safety of the combination and subjective outcomes were also assessed.
Methods: 15 OSA patients received progressively increasing Ato-Dro doses (dose escalation was performed every week, starting from Ato-Dro 40-2.5 mg, then 80-5 mg and finally 80-10 mg). A clinical, in-lab polysomnography was performed at baseline, on Ato-Dro 80-5 and Ato-Dro 80-10 mg.
Results: Ato-Dro 80-10 mg did not significantly reduce AHI4 and hypoxic burden and yielded limited clinical benefit vs. baseline and atomoxetine alone. However, Ato-Dro 80-5 mg did improve OSA severity (ΔAHI=8.3[0.3, 16.3] events/h; mean[CI]; Δhypoxic burden=37.7[12.5, 62.7] %min/hr) and multiple subjective outcomes vs. baseline and/or atomoxetine alone. Ato-Dro administration was characterized by several potentially harmful side effects and treatment discontinuation in 1/3 of cases.
Conclusions: Ato-Dro 80-5 mg might be useful to reduce OSA severity and led to subjective improvement in those who could tolerate the combination. However, given the numerous side effects and the exploratory nature of this open-label study, our results warrant further validation in larger trials.
Clinical trial registration: Registry: ClinicalTrials.gov; Identifier: NCT05101122; Title: Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED) (SEED); URL: https://clinicaltrials.gov/ct2/show/NCT05101122.
Keywords: OSA alternative treatments, cannabinoids, pharmacotherapy
© 2023 American Academy of Sleep Medicine.
Similar articles
-
Effects of atomoxetine plus a hypnotic on obstructive sleep apnea severity in patients with a moderately collapsible pharyngeal airway.J Clin Sleep Med. 2023 Feb 3. doi: 10.5664/jcsm.10464. Online ahead of print.PMID: 36734173
-
One Month Dosing of Atomoxetine plus Oxybutynin in Obstructive Sleep Apnea: A Randomized, Placebo-controlled Trial.Ann Am Thorac Soc. 2022 Dec 20. doi: 10.1513/AnnalsATS.202206-492OC. Online ahead of print.PMID: 36538809
-
Different antimuscarinics when combined with atomoxetine have differential effects on obstructive sleep apnea severity.J Appl Physiol (1985). 2021 May 1;130(5):1373-1382. doi: 10.1152/japplphysiol.01074.2020. Epub 2021 Mar 18.PMID: 33734828 Free PMC article. Clinical Trial.
-
[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].Encephale. 2005 May-Jun;31(3):337-48. doi: 10.1016/s0013-7006(05)82399-1.PMID: 16142049 Review. French.
-
Combined noradrenergic plus antimuscarinic agents for obstructive sleep apnea – A systematic review and meta-analysis of randomized controlled trials.Sleep Med Rev. 2022 Aug;64:101649. doi: 10.1016/j.smrv.2022.101649. Epub 2022 May 28.PMID: 35709641 Review.